Sign in
EQ Stock Price, Chart, Stats & News
Equillium, Inc.
Save
Equillium, Inc. (EQ) does not currently pay a dividend.
105.59M
Market cap
–
Current P/E
1.53x
Forward P/E
EQ chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -70.24% |
ROE | -119.19% |
D/E | 0.03x |
Interest coverage ratio | – |
EQ valuation
P/E | – |
P/S | – |
P/B | 6.04x |
P/CF | -7.59x |
P/FCF | -2.93x |
P/OCF | -7.59x |
PEG | -0.44x |
EV multiple | -4.10x |
About
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis.
Similar securities
Based on sector and market capitalization
Report issue